Development and testing of a rapid diagnostic test for bubonic and pneumonic plague

被引:161
作者
Chanteau, S
Rahalison, L
Ralafiarisoa, L
Foulon, J
Ratsitorahina, M
Ratsifasoamanana, L
Carniel, E
Nato, A
机构
[1] WHO, Collaborating Ctr Plague, Inst Pasteur Madagascar, Antananarivo, Madagascar
[2] Minist Hlth, Plague Natl Control Programme, Antananarivo, Madagascar
[3] WHO, Collaborating Ctr Yersinia, Inst Pasteur, Paris, France
关键词
D O I
10.1016/S0140-6736(03)12270-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Plague is often fatal without prompt and appropriate treatment. It affects mainly poor and remote populations. Late diagnosis is one of the major causes of human death and spread of the disease, since it limits the effectiveness of control measures. We aimed to develop and assess a rapid diagnostic test (RDT) for plague. Methods We developed a test that used monoclonal antibodies to the F1 antigen of Yersinia pestis. Sensitivity and specificity were assessed with a range of bacterial cultures and clinical samples, and compared with findings from available ELISA and bacteriological tests for plague. Samples from patients thought to have plague were tested with the RDT in the laboratory and by health workers in 26 pilot sites in Madagascar. Findings The RDT detected concentrations of F1 antigen as low as 0.5 ng/mL in up to 15 min, and had a shelf life of 21 days at 60degreesC. Its sensitivity and specificity were both 100%. RDT detected 41.6% and 31% more positive clinical specimens than did bacteriological methods and ELISA, respectively. The agreement rate between tests done at remote centres and in the laboratory was 89.8%. With the combination of bacteriological methods and F1 ELISA as reference standard, the positive and negative predictive values of the ROT were 90.6% and 86.7%, respectively. Interpretation Our RDT is a specific, sensitive, and reliable test that can easily be done by health workers at the patient's bedside, for the rapid diagnosis of pneumonic and bubonic plague. This test will be of key importance for the control of plague in endemic countries.
引用
收藏
页码:211 / 216
页数:6
相关论文
共 21 条
[1]  
BAKER EE, 1952, J IMMUNOL, V68, P131
[2]   Bioterrorism [J].
Bellamy, RJ ;
Freedman, AR .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (04) :227-234
[3]  
BIMBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
[4]   Epidemiologic features of four successive annual outbreaks of bubonic plague in Mahajanga, Madagascar [J].
Boisier, P ;
Rahalison, L ;
Rasolomaharo, M ;
Ratsitorahina, M ;
Mahafaly, M ;
Razafimahefa, M ;
Duplantier, JM ;
Ratsifasoamanana, L ;
Chanteau, S .
EMERGING INFECTIOUS DISEASES, 2002, 8 (03) :311-316
[5]  
BRUBAKER R R, 1970, Infection and Immunity, V1, P446
[6]   Current epidemiology of human plague in Madagascar [J].
Chanteau, S ;
Ratsitorahina, M ;
Rahalison, L ;
Rasoamanana, B ;
Chan, F ;
Boisier, P ;
Rabeson, D ;
Roux, J .
MICROBES AND INFECTION, 2000, 2 (01) :25-31
[7]   Plague, a reemerging disease in Madagascar [J].
Chanteau, S ;
Ratsifasoamanana, L ;
Rasoamanana, B ;
Rahalison, L ;
Randriambelosoa, J ;
Roux, J ;
Rabeson, D .
EMERGING INFECTIOUS DISEASES, 1998, 4 (01) :101-104
[8]   F1 antigenaemia in bubonic plague patients, a marker of gravity and efficacy of therapy [J].
Chanteau, S ;
Rabarijaona, L ;
O'Brien, T ;
Rahalison, L ;
Hager, J ;
Boisier, P ;
Burans, J ;
Rasolomaharo, M .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1998, 92 (05) :572-573
[9]  
Chanteau S, 2000, INT J MED MICROBIOL, V290, P279
[10]  
CHEN TH, 1966, B WORLD HEALTH ORGAN, V34, P911